Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression.

Neilan TG, Jassal DS, Scully MF, Chen G, Deflandre C, McAllister H, Kay E, Austin SC, Halpern EF, Harmey JH, Fitzgerald DJ.

Eur Heart J. 2006 May;27(10):1251-6. Epub 2006 Apr 19.

PMID:
16624831
2.

Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumor suppression.

Kuramochi Y, Takagi H, Morita T.

Eur Heart J. 2006 Nov;27(21):2610-1; author reply 2611. Epub 2006 Oct 3. No abstract available.

PMID:
17018546
3.

Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.

Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M.

Int Immunopharmacol. 2005 Feb;5(2):281-8.

PMID:
15652759
4.

The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.

Bruynzeel AM, Mul PP, Berkhof J, Bast A, Niessen HW, van der Vijgh WJ.

Cancer Chemother Pharmacol. 2006 Nov;58(5):699-702. Epub 2006 Mar 25.

PMID:
16565833
5.

Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.

van Almen GC, Swinnen M, Carai P, Verhesen W, Cleutjens JP, D'hooge J, Verheyen FK, Pinto YM, Schroen B, Carmeliet P, Heymans S.

J Mol Cell Cardiol. 2011 Sep;51(3):318-28. doi: 10.1016/j.yjmcc.2011.05.010. Epub 2011 May 23.

PMID:
21624372
6.

Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy.

Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Ogino A, Maruyama R, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H.

Lab Invest. 2007 May;87(5):440-55. Epub 2007 Mar 5.

7.

Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy.

Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Khai NC, Maruyama R, Ogino A, Minatoguchi S, Fujiwara T, Fujiwara H.

Circulation. 2006 Jan 31;113(4):535-43.

8.

Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin.

Neilan TG, Doherty GA, Chen G, Deflandre C, McAllister H, Butler RK, McClelland SE, Kay E, Ballou LR, Fitzgerald DJ.

Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H532-6. Epub 2006 Apr 14.

PMID:
16617129
9.

The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.

Breistøl K, Hendriks HR, Berger DP, Langdon SP, Fiebig HH, Fodstad O.

Eur J Cancer. 1998 Sep;34(10):1602-6.

PMID:
9893636
10.

The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis.

Frias MA, Somers S, Gerber-Wicht C, Opie LH, Lecour S, Lang U.

Cardiovasc Res. 2008 Oct 1;80(1):69-77. doi: 10.1093/cvr/cvn171. Epub 2008 Jun 20.

PMID:
18567640
11.

Fatty acids ameliorate doxorubicin-induced intracellular ca2+ increase and apoptosis in rat cardiomyocytes.

Park KH, Kim SY, Gul R, Kim BJ, Jang KY, Chung HT, Sohn DH.

Biol Pharm Bull. 2008 May;31(5):809-15.

12.

Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.

Xiang P, Deng HY, Li K, Huang GY, Chen Y, Tu L, Ng PC, Pong NH, Zhao H, Zhang L, Sung RY.

Cancer Chemother Pharmacol. 2009 Jan;63(2):343-9. doi: 10.1007/s00280-008-0744-4. Epub 2008 Apr 1.

PMID:
18379782
13.

Protective effect of Spirulina against doxorubicin-induced cardiotoxicity.

Khan M, Shobha JC, Mohan IK, Naidu MU, Sundaram C, Singh S, Kuppusamy P, Kutala VK.

Phytother Res. 2005 Dec;19(12):1030-7.

PMID:
16372368
14.

Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy.

Hamed S, Barshack I, Luboshits G, Wexler D, Deutsch V, Keren G, George J.

Eur Heart J. 2006 Aug;27(15):1876-83. Epub 2006 May 26.

PMID:
16731534
15.

Granulocyte colony-stimulating factor protects cardiac mitochondria in the early phase of cardiac injury.

Hiraumi Y, Iwai-Kanai E, Baba S, Yui Y, Kamitsuji Y, Mizushima Y, Matsubara H, Watanabe M, Watanabe K, Toyokuni S, Matsubara H, Nakahata T, Adachi S.

Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H823-32. doi: 10.1152/ajpheart.00774.2008. Epub 2009 Jan 9.

PMID:
19136605
16.

Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy.

Wang J, Zhang J, Sun J, Han J, Xi Y, Wu G, Duan KX, Zhang M, Zhou S, Liu Q.

Med Hypotheses. 2011 May;76(5):695-6. doi: 10.1016/j.mehy.2011.01.036. Epub 2011 Feb 22.

PMID:
21345596
17.

Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice.

Hou G, Dick R, Abrams GD, Brewer GJ.

J Lab Clin Med. 2005 Nov;146(5):299-303.

PMID:
16242529
18.

In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.

Ogawara K, Un K, Tanaka K, Higaki K, Kimura T.

J Control Release. 2009 Jan 5;133(1):4-10. doi: 10.1016/j.jconrel.2008.09.008. Epub 2008 Sep 20.

PMID:
18840484
19.

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.

J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.

PMID:
18695136
20.

Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction.

Hydock DS, Lien CY, Schneider CM, Hayward R.

Med Sci Sports Exerc. 2008 May;40(5):808-17. doi: 10.1249/MSS.0b013e318163744a.

PMID:
18408619

Supplemental Content

Support Center